2023 World Conference on Lung Cancer (Posters)-EP07.04. Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China

EP07.04. Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed the diagnosis, treatment patterns, and outcomes of patients with RET fusion-positive non-small cell lung cancer (NSCLC) in China. RET fusions are rare oncogenic drivers found in about 1-2% of NSCLC cases and are associated with a higher incidence of brain metastasis. Selective RET inhibitors have shown clinical benefits for first-line or subsequent-line therapy in advanced RET fusion-positive NSCLC. The study included 121 patients with RET fusion-positive NSCLC, and the majority of them were initially diagnosed with early-stage disease. Biomarker testing for RET was most commonly performed at the initial diagnosis, regardless of the disease stage, using next-generation sequencing (NGS) on tissue samples. The most prevalent RET fusion partners detected were KIF5B and CCDC6. In the early-stage cohort, most patients received primary treatments such as lung surgery or radiotherapy, with a disease recurrence rate of 11.8% within 5 years of follow-up. In the advanced cohort, platinum-based chemotherapy alone was the primary systemic therapy at first-line treatment. Other treatments included non-platinum-based chemotherapy, immune checkpoint inhibitors (ICIs), and tyrosine kinase inhibitors (TKIs). The median progression-free survival was 9.22 months for chemotherapy and 10.55 months for ICIs. The median overall survival was 30.7 months. Overall, the study found that the biomarker testing pattern for RET in NSCLC patients in China was compliant with recommendations, and the most common RET fusion partner was KIF5B. The use of platinum-based chemotherapy as first-line treatment in advanced NSCLC was consistent with previous studies.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

RET fusion-positive NSCLC

diagnosis

treatment patterns

China

biomarker testing

KIF5B

CCDC6

platinum-based chemotherapy

immune checkpoint inhibitors

progression-free survival